Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates

PLoS Neglected Tropical Diseases

Volumn 6, Issue 3, 2012, Pages

  Mire, Chad E ^a,b   Miller, Andrew D ^c   Carville, Angela ^c   Westmoreland, Susan V ^c   Geisbert, Joan B ^a,b   Mansfield, Keith G ^c   Feldmann, Heinz ^d   Hensley, Lisa E ^e   Geisbert, Thomas W ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FILOVIRUS GLYCOPROTEIN; RECOMBINANT VACCINE; RECOMBINANT VESICULAR STOMATITIS VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS VECTOR; GLYCOPROTEIN; LIVE VACCINE; VIRUS PROTEIN; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATAXIA; AUTOPSY; BASAL GANGLION; BRAIN STEM; CEREBELLUM; CONTROLLED STUDY; EBOLA VIRUS; FRONTAL CORTEX; GLIOSIS; HISTOPATHOLOGY; INFLAMMATORY INFILTRATE; MACACA FASCICULARIS; MALE; MARBURG VIRUS; NECROSIS; NERVE DEGENERATION; NEUROLOGIC DISEASE; NEUROVIRULENCE; NONHUMAN; OCCIPITAL CORTEX; REAL TIME POLYMERASE CHAIN REACTION; SPINAL CORD; THALAMUS; TREMOR; VESICULAR STOMATITIS VIRUS; VIRUS ISOLATION; VIRUS LOAD; VIRUS VIRULENCE; ANIMAL; GENE VECTOR; GENETICS; IMMUNOLOGY; MACACA; PATHOGENICITY; PATHOLOGY; PRIMATE DISEASE; VIRUS ENCEPHALITIS;

ANIMALS; EBOLAVIRUS; ENCEPHALITIS, VIRAL; GENETIC VECTORS; GLYCOPROTEINS; MACACA; MALE; MARBURGVIRUS; PRIMATE DISEASES; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VESICULOVIRUS; VIRAL PROTEINS; VIRAL VACCINES;

EID: 84859181562     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001567     Document Type: Article

References (68)

1. Feldmann H, Geisbert TW, Jahrling PB, Klenk HD, Netesov SV, et al.eds. (2004) Filoviridae London Elsevier/Academic Press pp. 645-653.
2. Sanchez A, Geisbert TW, Feldmann H, eds. (2006) (2006) Filoviridae: Marburg and Ebola Viruses. 5th ed Philadelphia Lippincott Williams & Wilkins pp. 1409-1448.
3. Towner JS, Sealy TK, Khristova ML, Albarino CG, Conlan S, et al. (2008) Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog 4: e1000212.
4. Hartman AL, Towner JS, Nichol ST, (2010) Ebola and marburg hemorrhagic fever. Clin Lab Med 30: 161-177.
5. Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A, (1998) Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 251: 28-37.
6. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ, (2000) Development of a preventive vaccine for Ebola virus infection in primates. Nature 408: 605-609.
7. Sullivan NJ, Geisbert TW, Geisbert JB, Xu L, Yang ZY, et al. (2003) Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424: 681-684.
8. Jones SM, Feldmann H, Stroher U, Geisbert JB, Fernando L, et al. (2005) Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 11: 786-790.
9. Daddario-DiCaprio KM, Geisbert TW, Geisbert JB, Stroher U, Hensley LE, et al. (2006) Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J Virol 80: 9659-9666.
10. Sullivan NJ, Geisbert TW, Geisbert JB, Shedlock DJ, Xu L, et al. (2006) Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med 3: e177.
11. Geisbert TW, Daddario-Dicaprio KM, Geisbert JB, Reed DS, Feldmann F, et al. (2008) Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine 26: 6894-6900.
12. Geisbert TW, Geisbert JB, Leung A, Daddario-DiCaprio KM, Hensley LE, et al. (2009) Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus. J Virol 83: 7296-7304.
13. Geisbert TW, Bailey M, Geisbert JB, Asiedu C, Roederer M, et al. (2010) Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates. J Virol 84: 10386-10394.
14. Bukreyev A, Rollin PE, Tate MK, Yang L, Zaki SR, et al. (2007) Successful topical respiratory tract immunization of primates against Ebola virus. J Virol 81: 6379-6388.
15. Swenson DL, Wang D, Luo M, Warfield KL, Woraratanadharm J, et al. (2008) Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin Vaccine Immunol 15: 460-467.
16. Swenson DL, Warfield KL, Larsen T, Alves DA, Coberley SS, et al. (2008) Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses. Expert Rev Vaccines 7: 417-429.
17. Warfield KL, Swenson DL, Olinger GG, Kalina WV, Aman MJ, et al. (2007) Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 196 (Suppl 2): S430-437.
18. Qiu X, Fernando L, Alimonti JB, Melito PL, Feldmann F, et al. (2009) Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS One 4: e5547.
19. Hensley LE, Mulangu S, Asiedu C, Johnson J, Honko AN, et al. (2010) Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. PLoS Pathog 6: e1000904.
20. Pratt WD, Wang D, Nichols DK, Luo M, Woraratanadharm J, et al. (2010) Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector. Clin Vaccine Immunol 17: 572-581.
21. Mehedi M, Falzarano D, Seebach J, Hu X, Carpenter MS, et al. (2011) A new Ebola virus nonstructural glycoprotein expressed through RNA editing. J Virol 85: 5406-5414.
22. Brody JA, Fischer GF, Peralta PH, (1967) Vesicular stomatitis virus in Panama. Human serologic patterns in a cattle raising area. Am J Epidemiol 86: 158-161.
23. Johnson KM, Vogel JE, Peralta PH, (1966) Clinical and serological response to laboratory-acquired human infection by Indiana type vesicular stomatitis virus (VSV). Am J Trop Med Hyg 15: 244-246.
24. Roberts A, Buonocore L, Price R, Forman J, Rose JK, (1999) Attenuated vesicular stomatitis viruses as vaccine vectors. J Virol 73: 3723-3732.
25. Rose NF, Marx PA, Luckay A, Nixon DF, Moretto WJ, et al. (2001) An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 106: 539-549.
26. Rose NF, Roberts A, Buonocore L, Rose JK, (2000) Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1. J Virol 74: 10903-10910.
27. Egan MA, Chong SY, Rose NF, Megati S, Lopez KJ, et al. (2004) Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes. AIDS Res Hum Retroviruses 20: 989-1004.
28. Schlereth B, Rose JK, Buonocore L, ter Meulen V, Niewiesk S, (2000) Successful vaccine-induced seroconversion by single-dose immunization in the presence of measles virus-specific maternal antibodies. J Virol 74: 4652-4657.
29. Schlereth B, Buonocore L, Tietz A, Meulen Vt V, Rose JK, et al. (2003) Successful mucosal immunization of cotton rats in the presence of measles virus-specific antibodies depends on degree of attenuation of vaccine vector and virus dose. J Gen Virol 84: 2145-2151.
30. Kahn JS, Roberts A, Weibel C, Buonocore L, Rose JK, (2001) Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge. J Virol 75: 11079-11087.
31. Reuter JD, Vivas-Gonzalez BE, Gomez D, Wilson JH, Brandsma JL, et al. (2002) Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease. J Virol 76: 8900-8909.
32. Roberts A, Reuter JD, Wilson JH, Baldwin S, Rose JK, (2004) Complete protection from papillomavirus challenge after a single vaccination with a vesicular stomatitis virus vector expressing high levels of L1 protein. J Virol 78: 3196-3199.
33. Kapadia SU, Rose JK, Lamirande E, Vogel L, Subbarao K, et al. (2005) Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology 340: 174-182.
34. Garbutt M, Liebscher R, Wahl-Jensen V, Jones S, Moller P, et al. (2004) Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 78: 5458-5465.
35. Geisbert TW, Daddario-Dicaprio KM, Lewis MG, Geisbert JB, Grolla A, et al. (2008) Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog 4: e1000225.
36. Daddario-DiCaprio KM, Geisbert TW, Stroher U, Geisbert JB, Grolla A, et al. (2006) Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. Lancet 367: 1399-1404.
37. Feldmann H, Jones SM, Daddario-DiCaprio KM, Geisbert JB, Stroher U, et al. (2007) Effective post-exposure treatment of Ebola infection. PLoS Pathog 3: e2.
38. Geisbert TW, Daddario-DiCaprio KM, Williams KJ, Geisbert JB, Leung A, et al. (2008) Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates. J Virol 82: 5664-5668.
39. Geisbert TW, Hensley LE, Geisbert JB, Leung A, Johnson JC, et al. (2010) Postexposure treatment of Marburg virus infection. Emerg Infect Dis 16: 1119-1122.
40. Gunther S, Feldmann H, Geisbert TW, Hensley LE, Rollin PE, et al. (2011) Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis 204 (Suppl 3): S785-790.
41. Fournier JG, Robain O, Cerutti I, Tardivel I, Chany-Fournier F, et al. (1988) Detection of vesicular stomatitis virus (VSV) RNA in the central nervous system of infected mice by in situ hybridization. Acta Neuropathol (Berl) 75: 554-556.
42. Fultz PN, Shadduck JA, Kang CY, Streilein JW, (1981) Genetic analysis of resistance to lethal infections of vesicular stomatitis virus in Syrian hamsters. Infect Immun 32: 1007-1013.
43. Huneycutt BS, Plakhov IV, Shusterman Z, Bartido SM, Huang A, et al. (1994) Distribution of vesicular stomatitis virus proteins in the brains of BALB/c mice following intranasal inoculation: an immunohistochemical analysis. Brain Res 635: 81-95.
44. Miyoshi K, Harter DH, Hsu KC, (1971) Neuropathological and immunofluorescence studies of experimental vesicular stomatitis virus encephalitis in mice. J Neuropathol Exp Neurol 30: 266-277.
45. Plakhov IV, Arlund EE, Aoki C, Reiss CS, (1995) The earliest events in vesicular stomatitis virus infection of the murine olfactory neuroepithelium and entry of the central nervous system. Virology 209: 257-262.
46. Reiss CS, Plakhov IV, Komatsu T, (1998) Viral replication in olfactory receptor neurons and entry into the olfactory bulb and brain. Ann N Y Acad Sci 855: 751-761.
47. Sur JH, Allende R, Doster AR, (2003) Vesicular stomatitis virus infection and neuropathogenesis in the murine model are associated with apoptosis. Vet Pathol 40: 512-520.
48. van den Pol AN, Dalton KP, Rose JK, (2002) Relative neurotropism of a recombinant rhabdovirus expressing a green fluorescent envelope glycoprotein. J Virol 76: 1309-1327.
49. Olitsky PK, Cox HR, Syverton JT, (1934) Comparative studies on the viruses of vesicular stomatitis and equine encephalomyelitis (1). Journal of Experimental Medicine 59: 159-171.
50. Frank AH, Appleby A, Seibold HR, (1945) Experimental Intracerebral Infection of Horses, Cattle, and Sheep with the Virus of Vesicular Stomatitis. American Journal of Veterinary Research 6: 28-38.
51. Sharova OK, Rozina EE, Shteinberg LS, Gordienko NM, Kolyanova IS, (1979) Morphological characterisitcs of the pathological process in the central nervous system of monkeys infected with variants of measles virus strain L-16. Acta Virol 23: 393-397.
52. Yamanouchi K, Uchida N, Katow S, Sato TA, Kobune K, (1976) Growth of measles virus in nervous tissues. IV. Neurovirulence of wild measles and SSPE viruses in monkeys. Jpn J Med Sci Biol 29: 177-186.
53. Levenbuk IS, Nikolayeva MA, Chigirinsky AE, Ralf NM, Kozlov VG, et al. (1979) On the morphological evaluation of the neurovirulence safety of attenuated mumps virus strains in monkeys. J Biol Stand 7: 9-19.
54. Maximova O, Dragunsky E, Taffs R, Snoy P, Cogan J, et al. (1996) Monkey neurovirulence test for live mumps vaccine. Biologicals 24: 223-224.
55. Levenbook IS, Pelleu LJ, Elisberg BL, (1987) The monkey safety test for neurovirulence of yellow fever vaccines: the utility of quantitative clinical evaluation and histological examination. J Biol Stand 15: 305-313.
56. Marchevsky RS, Freire MS, Coutinho ES, Galler R, (2003) Neurovirulence of yellow fever 17DD vaccine virus to rhesus monkeys. Virology 316: 55-63.
57. Nathanson N, Horn SD, (1992) Neurovirulence tests of type 3 oral poliovirus vaccine manufactured by Lederle Laboratories, 1964-1988. Vaccine 10: 469-474.
58. Wood DJ, Macadam AJ, (1997) Laboratory tests for live attenuated poliovirus vaccines. Biologicals 25: 3-15.
59. Johnson JE, Nasar F, Coleman JW, Price RE, Javadian A, et al. (2007) Neurovirulence properties of recombinant vesicular stomatitis virus vectors in non-human primates. Virology 360: 36-49.
60. Lawson ND, Stillman EA, Whitt MA, Rose JK, (1995) Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci U S A 92: 4477-4481.
61. Mire CE, Whitt MA, (2011) The protease-sensitive loop of the vesicular stomatitis virus matrix protein is involved in virus assembly and protein translation. Virology.
62. Bi Z, Barna M, Komatsu T, Reiss CS, (1995) Vesicular stomatitis virus infection of the central nervous system activates both innate and acquired immunity. J Virol 69: 6466-6472.
63. Rubin SA, Afzal MA, (2011) Neurovirulence safety testing of mumps vaccines-historical perspective and current status. Vaccine 29: 2850-2855.
64. Geisbert TW, Hensley LE, Larsen T, Young HA, Reed DS, et al. (2003) Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am J Pathol 163: 2347-2370.
65. Hensley LE Alves DA, Geisbert JB, Fritz EA, Reed C, et al. (2011) Pathogenesis of Marburg hemorrhagic fever in cynomolgus macaques. J Infect Dis.
66. Jayakar HR, Whitt MA, (2002) Identification of two additional translation products from the matrix (M) gene that contribute to vesicular stomatitis virus cytopathology. J Virol 76: 8011-8018.
67. Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, et al. (2003) VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4: 263-275.
68. Jones SM, Stroeher U, Fernando L, Qiu XG, Alimonti J, et al. (2007) Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. Journal of Infectious Diseases 196: S404-S412.